Tamoxifen (TAM) is a selective estrogen receptor modulator that is used in the treatment of
breast cancer. As there are estrogen receptors in the retina, retinal pigment epithelium, and …

Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive
(HER+) breast cancer in both pre-and post-menopausal patients and may undergo …

Purpose: To study structural chorioretinal changes in tamoxifen-treated patients. Methods:
Cross-sectional case–control study comparing structural chorioretinal aspects in tamoxifen …

Purpose: To evaluate choroidal thickness, ganglion cell complex (GCC) and photoreceptor
outer segment (PROS) length were measured in patients with breast cancer undergoing …

Tamoxifen, a nonsteroidal estrogen receptor (ER) antagonist, is used routinely as a
chemotherapeutic agent for ER-positive breast cancer. However, it is also causes side …

Background Central serous chorioretinopathy (CSC) is preferential cocurated in males,
however the associations between sex hormones and CSC incidence or progression …

Purpose To evaluate the vascular structure of the choroid and each retinal layer in patients
with breast cancer on tamoxifen therapy and compare them with healthy subjects. Materials …

Background: The present study describes our 10-year experience with uveoretinal adverse
events that manifest because of chemotherapy. Methods: A retrospective chart review was …

Background: Tamoxifen is a selective estrogen receptor modulator that is mainly used as
treatment for patients with hormone receptor-positive breast cancer; the prevalence of …

This is a first ever report describing a case of acute bilateral central serous chorioretinopathy
which developed shortly after the consumption of levonorgestrel as emergency …